Loading provider…
Loading provider…
Rheumatology Physician in Los Angeles, CA
NPI: 1285655852Primary Practice Location
RONALD REAGAN UCLA MEDICAL CENTER
757 Westwood Plz, Los Angeles, CA
Primary Employer
UCLA Medical Plaza
uclahealth.org
HQ Phone
Get MD Maureen's Phone NumberMobile
Get MD Maureen's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
2001 - 2026
IL State Medical License
1997 - 2002
CA State Medical License

American Board of Internal Medicine
Rheumatology
UCLA David Geffen School of Medicine/UCLA Medical Center
Fellowship • Rheumatology
2001 - 2003
Rush University Medical Center
Residency • Internal Medicine
1997 - 2001
Pritzker School of Medicine
pritzker.uchicago.edu
Medical School
Until 1997
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 33 | 51 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 24 | 36 |
Authors: Deborah Mccurdy, Miriam Parsa, Alice Hoftman, Jennifer Grossman, Bevra Hahn
Journal: Arthritis Res Ther
Publication Date: 2013-01-23
Authors: Sangmee Bae, Jennifer Wang, Linh Truong, John Fitzgerald, Christina Charles-Schoeman, Howard Yang
Journal: Rheumatol Int
Publication Date: 2023-06-27
Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here?
Authors: Daniel Furst, Dinesh Khanna
Publication Date: 2004-04
Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators: Autoimmunity Centers of Excellence, Rho Federal Systems Division, Inc.
Intervention / Treatment: BIOLOGICAL: BNT162b2, Bivalent, DRUG: Withhold IS (B cell depletion therapy), BIOLOGICAL: Ad26.COV2.S, BIOLOGICAL: Moderna mRNA-1273, BIOLOGICAL: BNT162b2, DRUG: Continue IS (MMF or MPA), DRUG: Continue IS (MTX), BIOLOGICAL: Continue IS (B cell depletion therapy), BIOLOGICAL: Monovalent [B.1.351] CoV2 preS dTM-AS03, DRUG: Withhold IS (MMF or MPA), DRUG: Withhold IS (MTX), BIOLOGICAL: Moderna mRNA-1273, Bivalent
Lead Sponsor: Northwell Health
Collaborators: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Intervention / Treatment: DRUG: Nelfinavir